Developmental Teratogeny Test

BioVenic delivers fully standardized multi-species aquatic developmental teratogenicity test (DTT) services to enable precise assessment of developmental toxic risks in aquatic organisms. As a professional subchronic toxicological testing method, DTT detects sublethal morphological defects and developmental disorders in aquatic embryos exposed to exogenous toxic substances. Distinct from acute lethal toxicity tests, this 3Rs-compliant technique focuses on long-term developmental damages rather than immediate mortality, serving as a core tool for chemical safety verification, drug teratogenicity evaluation and aquatic ecosystem protection.

Ideal Projects We Support

• Pharmaceutical Teratogenic Safety Evaluation: Test aquatic embryonic teratogenic risks of new pharmaceutical compounds, verifying drug safety for childbearing-age population application and preclinical toxicological assessment.
• Environmental Toxin Risk Research: Explore teratogenic damages of heavy metals, endocrine disruptors and water pollutants to aquatic embryos, supporting environmental health risk assessment.
• Developmental Toxicology Mechanism Study: Analyze molecular and cellular pathways of toxin-induced developmental malformations, enrich basic research on aquatic teratogenic toxicology mechanisms.

Fig 1. Application: triptolide, aconitine, chlorogenic acid, treatment to zebrafish at 5 dpf. ^1,3

Common Challenges We Help Address

• Natural embryonic individual differentiation easily interferes with subtle teratogenic phenotypes, causing false judgment of toxin-induced malformations.
• Low-concentration toxin stress leads to mild developmental retardation, which is difficult to quantify and distinguish from normal developmental differences.
• Long-term embryonic incubation is susceptible to water quality, temperature and microbial interference, disrupting stable developmental states.
• Manual identification of diverse teratogenic phenotypes is prone to omission, reducing the comprehensiveness of toxicity evaluation.
• Lack of unified teratogenic index calculation standards leads to inconsistent toxicity potency evaluation results.

Standardized Service Workflow

BioVenic builds a standardized six-step full-process DTT workflow, realizing standardized control from embryo incubation to final index calculation, ensuring high repeatability and authority of experimental results.

1. Embryo Incubation & Toxin Exposure: Screen high-quality uniform aquatic fertilized embryos, set five 2-fold gradient concentrations of test substances, and conduct continuous toxin exposure incubation from 0 to 96 hours post-fertilization.
2. Automated Imaging Collection: After the incubation cycle is completed, use professional automated imaging equipment to collect full-view embryonic morphological images for subsequent teratogenicity analysis.
3. Dynamic Developmental Monitoring: Continuously observe the whole embryonic development process, record key developmental nodes, embryonic coagulation status and early abnormal phenotypic changes in real time.
4. Professional Phenotype Evaluation: Adopt a validated teratogenic phenotypic marker system to comprehensively identify and classify various toxin-induced embryonic morphological abnormalities and developmental defects.
5. Teratogenicity & Mortality Correlation Assessment: Systematically count embryonic mortality and teratogenic rate of each concentration group, analyze the correlation between toxin concentration, lethality and developmental malformation severity.
6. Teratogenic Index Calculation: Calculate the teratogenic potency index based on matched mortality and teratogenicity data across all concentration groups, quantitatively evaluate the developmental teratogenic risk of test substances.

Fig 2. Workflow of developmental teratogeny test. (BioVenic Original)

Why Choose BioVenic

• Professional Teratology Technical Team: Equipped with professional aquatic developmental toxicologists, proficient in identifying various subtle embryonic teratogenic phenotypes and standardized teratogenic index calculation.
• Intelligent & Standardized System: Adopt automated imaging monitoring and standardized phenotypic evaluation criteria to eliminate manual identification errors and improve data accuracy.
• High-Efficiency Customized Service: Provide exclusive experimental schemes according to test substance attributes, deliver accurate teratogenic risk assessment reports efficiently to support research and certification.

Core Application Scenarios

• Pharmaceutical Developmental Safety Verification

Evaluate the teratogenic risk of new drugs and pharmaceutical intermediates, providing toxicological data for clinical medication safety and preclinical research.

• Environmental Ecological Risk Assessment

Reveal the developmental damage mechanism of environmental toxins to aquatic embryos, providing biological basis for water pollution control and ecological protection.

• Basic Developmental Toxicology Research

Explore the molecular mechanism of toxin-induced embryonic malformation, promoting in-depth research on aquatic developmental biology and toxicology.

Published Research Background

A peer-reviewed study systematically validated zebrafish embryonic models as reliable tools for developmental toxicity assessment. The published research summarized characteristic teratogenic phenotypes including cardiac, neural and ocular malformations, and confirmed that aquatic embryo-based assays can sensitively detect sub-lethal developmental damage induced by exogenous chemicals. These published findings establish a standardized phenotypic evaluation framework for teratogenicity testing.

Building on these published research foundations, BioVenic optimizes standardized DTT pipelines with validated phenotypic marker panels. We deliver accurate, specification-compliant developmental teratogenicity testing services for diverse chemical and pharmaceutical samples.

Fig 3. Representative developmental malformations induced by teratogens in zebrafish embryos. ^2,3

Frequently Asked Questions

1. What is the core difference between DTT and conventional embryo acute toxicity test?
   FET focuses on acute embryonic lethality and calculates LC50, while DTT targets non-lethal teratogenic phenotypes and developmental retardation. DTT can capture subtle developmental hazards that acute tests cannot detect, realizing more comprehensive developmental risk evaluation.
2. What core teratogenic phenotypes are detected in standard DTT experiments?
   Our detection covers typical teratogenic indicators such as pericardial edema, spinal curvature, eye dysplasia, developmental delay, body malformation and embryonic coagulation, forming a complete quantitative teratogenic evaluation system.
3. What is the teratogenic index and what is its evaluation value?
   The teratogenic index is calculated based on toxin concentration, mortality and malformation rate, which can quantitatively reflect the teratogenic potency of test substances and accurately distinguish developmental hazard levels of different compounds.

Partner with BioVenic

BioVenic provides professional Aquatic Animal Developmental Teratogeny Test to support ecological risk evaluation and developmental toxicology research. Monitoring teratogenic changes during aquatic animal development is crucial for identifying the deformity risks posed by chemicals, pollutants and environmental stressors. Our proficient lab team adopts rigorous testing standards to capture developmental defects and deliver systematic, reliable experimental analysis. To discuss your specific project requirements, explore our technical capabilities, or receive a detailed quote for your study, please contact us. Our experts help you obtain authentic teratogenic test data to empower your academic and environmental research progress.

Our products and services are for research use only and cannot be used for any clinical purposes.

Related Services